{"id":"chromic-chloride","rwe":[{"pmid":"38885863","year":"2024","title":"Co-production of fermentable sugars and highly active lignin from eucalyptus via a mild preprocessing with diethylene glycol and chromic chloride.","finding":"","journal":"International journal of biological macromolecules","studyType":"Clinical Study"},{"pmid":"36976162","year":"2023","title":"Ecosystem Protection through Myco-Remediation of Chromium and Arsenic.","finding":"","journal":"Journal of xenobiotics","studyType":"Clinical Study"},{"pmid":"34470861","year":"2021","title":"Making Weak Antigens Strong: Coupling Antigens to Red Blood Cells.","finding":"","journal":"Cold Spring Harbor protocols","studyType":"Clinical Study"},{"pmid":"29207354","year":"2018","title":"Biomonitoring chromium III or VI soluble pollution by moss chlorophyll fluorescence.","finding":"","journal":"Chemosphere","studyType":"Clinical Study"},{"pmid":"27761845","year":"2017","title":"Effects of Excess Cr(3+) on Trace Element Contents in the Brain and Serum in Chicken.","finding":"","journal":"Biological trace element research","studyType":"Clinical Study"}],"_fda":{"id":"c50dd42d-ac9f-47e2-8582-2defcab2fb98","set_id":"b4d01ebb-a36e-44b7-028c-43c0ab2d13b4","openfda":{"unii":["KB1PCR9DMW"],"route":["INTRAVENOUS"],"rxcui":["204401"],"spl_id":["c50dd42d-ac9f-47e2-8582-2defcab2fb98"],"brand_name":["CHROMIUM"],"spl_set_id":["b4d01ebb-a36e-44b7-028c-43c0ab2d13b4"],"package_ndc":["0409-4093-11","0409-4093-01"],"product_ndc":["0409-4093"],"generic_name":["CHROMIC CHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CHROMIC CHLORIDE"],"manufacturer_name":["Hospira, Inc."],"application_number":["NDA018961"],"is_original_packager":[true]},"version":"23","warnings":["WARNINGS Direct intramuscular or intravenous injection of Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is contraindicated, as the acidic pH of the solution may cause considerable tissue irritation. Severe kidney disease may make it necessary to reduce or omit chromium and zinc doses because these elements are primarily eliminated in the urine. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration."],"pregnancy":["Pregnancy Animal reproduction studies have not been conducted with chromic chloride. It is also not known whether chromic chloride can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Chromic chloride should be given to a pregnant woman only if clearly indicated."],"overdosage":["OVERDOSAGE Trivalent chromium administered intravenously to TPN patients has been shown to be nontoxic when given at dosage levels of up to 250 mcg/day for two consecutive weeks. Reported toxic reactions to chromium include nausea, vomiting, ulcers of the gastrointestinal tract, renal and hepatic damage, convulsions and coma. The acute LD 50 for intravenous trivalent chromium in rats was reported as 10 to 18 mg/kg."],"description":["DESCRIPTION Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is a sterile, nonpyrogenic solution intended for use as an additive to intravenous solutions for total parenteral nutrition (TPN). Each mL of solution contains 20.5 mcg chromic chloride, hexahydrate and 9 mg sodium chloride. The solution contains no bacteriostat, antimicrobial agent, or added buffer. The pH is 2.0 (1.5 to 2.5); product may contain hydrochloric acid and/or sodium hydroxide for pH adjustment. The osmolarity is 0.308 mOsm/mL (calc.). Chromic Chloride, USP is chemically designated chromic chloride, hexahydrate CrCl 3 • 6H 2 O, a crystalline compound soluble in water. Sodium Chloride, USP is chemically designated NaCl, a white, crystalline compound freely soluble in water. The semi-rigid vial is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers. The small amount of water vapor that can pass through the plastic container wall will not significantly alter the drug concentration."],"precautions":["PRECAUTIONS General Do not use unless solution is clear and seal is intact. Chromium 4 mcg/mL (Chromic Chloride Injection, USP) should only be used in conjunction with a pharmacy directed admixture program using aseptic technique in a laminar flow environment; it should be used promptly and in a single operation without any repeated penetrations. Solution contains no preservatives; discard unused portion immediately after admixture procedure is completed. In assessing the contribution of chromium supplements to maintenance of glucose homeostasis, consideration should be given to the possibility that the patient may be diabetic. Geriatric Use An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Laboratory Tests Because chromium is present in the bloodstream in microgram quantities, routine measurement is impractical. If necessary, samples can be sent to a reference laboratory for assay. Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies to evaluate the carcinogenic potential of Chromium 4 mcg/mL (Chromic Chloride Injection, USP) have not been performed, nor have studies been done to assess mutagenesis or impairment of fertility. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is administered to a nursing woman. Pediatric Use See DOSAGE and ADMINISTRATION section. Safety and effectiveness in children have not been established. Pregnancy Animal reproduction studies have not been conducted with chromic chloride. It is also not known whether chromic chloride can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Chromic chloride should be given to a pregnant woman only if clearly indicated."],"how_supplied":["HOW SUPPLIED Chromium (Chromic Chloride Injection, USP) is supplied as follows: Unit of Sale Concentration NDC 0409-4093-01 40 mcg/10 mL Tray of 25 Single-dose plastic vials (4 mcg/mL) Store at 20 to 25ºC (68 to 77ºF). [See USP Controlled Room Temperature.] Distributed by Hospira, Inc., Lake Forest, IL 60045 USA LAB-1065-3.0 Revised: 4/2021 Hospira Logo"],"geriatric_use":["Geriatric Use An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"pediatric_use":["Pediatric Use See DOSAGE and ADMINISTRATION section. Safety and effectiveness in children have not been established."],"effective_time":"20241126","nursing_mothers":["Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is administered to a nursing woman."],"laboratory_tests":["Laboratory Tests Because chromium is present in the bloodstream in microgram quantities, routine measurement is impractical. If necessary, samples can be sent to a reference laboratory for assay."],"adverse_reactions":["ADVERSE REACTIONS None known."],"contraindications":["CONTRAINDICATIONS None known."],"how_supplied_table":["
Unit of SaleConcentration
NDC 0409-4093-0140 mcg/10 mL
Tray of 25 Single-dose plastic vials(4 mcg/mL)
"],"general_precautions":["General Do not use unless solution is clear and seal is intact. Chromium 4 mcg/mL (Chromic Chloride Injection, USP) should only be used in conjunction with a pharmacy directed admixture program using aseptic technique in a laminar flow environment; it should be used promptly and in a single operation without any repeated penetrations. Solution contains no preservatives; discard unused portion immediately after admixture procedure is completed. In assessing the contribution of chromium supplements to maintenance of glucose homeostasis, consideration should be given to the possibility that the patient may be diabetic."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Trivalent chromium is part of glucose tolerance factor, an essential activator of insulin-mediated reactions. Chromium helps to maintain normal glucose metabolism and peripheral nerve function. Providing chromium during TPN helps prevent deficiency symptoms including impaired glucose tolerance, ataxia, peripheral neuropathy and a confusional state similar to mild/moderate hepatic encephalopathy. Serum chromium is bound to transferrin (siderophilin) in the beta globulin fraction. Typical blood levels for chromium range from 1 to 5 mcg/liter, but blood levels are not considered a meaningful index of tissue stores. Administration of chromium supplements to chromium-deficient patients can result in normalization of the glucose tolerance curve from the diabetic-like curve typical of chromium deficiency. This response is viewed as a more meaningful indicator of chromium nutriture than serum chromium levels. Excretion of chromium is via the kidneys, ranging from 3 to 50 mcg/day. Biliary excretion via the small intestine may be an ancillary route, but only small amounts of chromium are believed to be excreted in this manner."],"indications_and_usage":["INDICATIONS AND USAGE Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for TPN. Administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms."],"spl_unclassified_section":["FOR I.V. USE ONLY AFTER DILUTION Plastic Vial Rx Only"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Chromium 4 mcg/mL (Chromic Chloride Injection, USP) contains 4 mcg chromium/mL and is administered intravenously only after dilution. The additive should be administered in a volume of fluid not less than 100 mL. For the adult receiving TPN, the suggested additive dosage is 10 to 15 mcg chromium/day (2.5 to 3.75 mL/day). The metabolically stable adult with intestinal fluid loss may require 20 mcg chromium/day (5 mL/day), with frequent monitoring of blood levels as a guideline for subsequent administration. For pediatric patients, the suggested additive dosage is 0.14 to 0.20 mcg/kg/day (0.035 to 0.05 mL/kg/day). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS ."],"drug_abuse_and_dependence":["DRUG ABUSE AND DEPENDENCE None known."],"spl_product_data_elements":["CHROMIUM CHROMIC CHLORIDE CHROMIC CHLORIDE CHROMIC CATION SODIUM CHLORIDE HYDROCHLORIC ACID SODIUM HYDROXIDE"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 10 mL Vial Label 10 mL Single-dose Vial CHROMIUM Chromic Chloride Inj., USP 40 mcg/10 mL (4 mcg/mL) Distributed by Hospira, Inc., Lake Forest, IL 60045 USA Hospira PRINCIPAL DISPLAY PANEL - 10 mL Vial Label","PRINCIPAL DISPLAY PANEL - 10 mL Vial Tray 10 mL Single-dose Vial Rx only NDC 0409-4093-01 Contains 25 of NDC 0409-4093-11 CHROMIUM Chromic Chloride Injection, USP 40 mcg/10 mL (4 mcg/mL) CAUTION: FOR INTRAVENOUS USE ONLY AFTER DILUTION. Hospira PRINCIPAL DISPLAY PANEL - 10 mL Vial Tray"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies to evaluate the carcinogenic potential of Chromium 4 mcg/mL (Chromic Chloride Injection, USP) have not been performed, nor have studies been done to assess mutagenesis or impairment of fertility."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Tyrosine-protein kinase Fyn","category":"target"},{"label":"FYN","category":"gene"},{"label":"EGFR","category":"gene"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Hospira","category":"company"},{"label":"Approved 1980s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"commonSideEffects":[],"specialPopulations":{"Pregnancy":"Chromic chloride should be given to pregnant woman only if clearly indicated.","Geriatric use":"Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.","Paediatric use":"Safety and effectiveness in children have not been established."}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CHROMIC CHLORIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:03:05.868388+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:03:47.888414+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:03:11.491925+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHROMIC CHLORIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:03:12.228241+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:03:04.756266+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:03:40.185684+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:03:04.756292+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200528/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:03:13.879604+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS None known.","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:03:17.805428+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA018961","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:03:04.756295+00:00"}},"allNames":"chromic chloride in plastic container","offLabel":[],"synonyms":["chromic chloride","chromic trichloride","chromium trichloride","chromic chloride hexahydrate"],"timeline":[{"date":"1986-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from HOSPIRA to Hospira"},{"date":"1986-06-26","type":"positive","source":"DrugCentral","milestone":"FDA approval (Hospira)"},{"date":"1987-05-05","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Abraxis Pharm)"},{"date":"2024-11-18","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"Chromic Chloride, marketed by Pfizer, is a TPN supplement that uniquely targets the inhibition of Tyrosine-protein kinase Fyn, positioning it in a niche but critical segment of the market. Its key strength lies in the protection of its composition patent, which does not expire until 2028, providing a significant barrier to generic competition. The primary risk is the competitive landscape, with multiple drugs targeting the same mechanism, including acalabrutinib, afatinib, amivantamab, astemizole, and axitinib, all of which are either already on the market or have strong patent protections.","approvals":[{"date":"1986-06-26","orphan":false,"company":"HOSPIRA","regulator":"FDA"}],"brandName":"Chromic Chloride In Plastic Container","ecosystem":[],"mechanism":{"target":"Epidermal growth factor receptor, Tyrosine-protein kinase Fyn","novelty":"Follow-on","targets":[{"gene":"FYN","source":"DrugCentral","target":"Tyrosine-protein kinase Fyn","protein":"Tyrosine-protein kinase Fyn"},{"gene":"EGFR","source":"DrugCentral","target":"Epidermal growth factor receptor","protein":"Epidermal growth factor receptor"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Chromic Chloride exerts its effects by competitively inhibiting the ATP-binding site of Tyrosine-protein kinase Fyn, thereby preventing the enzyme from phosphorylating its substrates."},"commercial":{"launchDate":"1986","_launchSource":"DrugCentral (FDA 1986-06-26, HOSPIRA)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5118","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CHROMIC%20CHLORIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHROMIC CHLORIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:36:28.016701","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T02:03:47.888502+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"acalabrutinib","drugSlug":"acalabrutinib","fdaApproval":"2017-10-31","patentExpiry":"Nov 24, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"afatinib","drugSlug":"afatinib","fdaApproval":"2013-07-12","patentExpiry":"Oct 10, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amivantamab","drugSlug":"amivantamab","fdaApproval":"2021-05-21","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"axitinib","drugSlug":"axitinib","fdaApproval":"2012-01-27","patentExpiry":"Jun 14, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"bacitracin","drugSlug":"bacitracin","fdaApproval":"1948-07-29","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"bosutinib","drugSlug":"bosutinib","fdaApproval":"2012-09-04","patentExpiry":"Nov 23, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"brigatinib","drugSlug":"brigatinib","fdaApproval":"2017-04-28","patentExpiry":"Nov 10, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"cabozantinib","drugSlug":"cabozantinib","fdaApproval":"2012-11-29","patentExpiry":"Oct 8, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"candesartan cilexetil","drugSlug":"candesartan-cilexetil","fdaApproval":"1998-06-04","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"chromic chloride","indications":{"approved":[{"id":"chromic-chloride-tpn-supplement","name":"TPN Supplement","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients receiving total parenteral nutrition (TPN)","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients receiving total parenteral nutrition (TPN)","diagnosticRequired":null,"brandNameForIndication":"Chromic Chloride In Plastic Container"},{"id":"chromic-chloride-prevent-chromium-deficiency","name":"Prevent Chromium Deficiency","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients at risk of chromium deficiency","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients at risk of chromium deficiency","diagnosticRequired":null,"brandNameForIndication":"Chromic Chloride In Plastic Container"}],"offLabel":[],"pipeline":[]},"currentOwner":"Hospira","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"acalabrutinib","brandName":"acalabrutinib","genericName":"acalabrutinib","approvalYear":"2017","relationship":"same-target"},{"drugId":"afatinib","brandName":"afatinib","genericName":"afatinib","approvalYear":"2013","relationship":"same-target"},{"drugId":"amivantamab","brandName":"amivantamab","genericName":"amivantamab","approvalYear":"2021","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"axitinib","brandName":"axitinib","genericName":"axitinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"bacitracin","brandName":"bacitracin","genericName":"bacitracin","approvalYear":"1948","relationship":"same-target"},{"drugId":"bosutinib","brandName":"bosutinib","genericName":"bosutinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"brigatinib","brandName":"brigatinib","genericName":"brigatinib","approvalYear":"2017","relationship":"same-target"},{"drugId":"cabozantinib","brandName":"cabozantinib","genericName":"cabozantinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"candesartan-cilexetil","brandName":"candesartan cilexetil","genericName":"candesartan cilexetil","approvalYear":"1998","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT03038282","phase":"NA","title":"Effects of Chromium on Insulin Resistance in Alzheimer Disease Patients","status":"UNKNOWN","sponsor":"Metabolic Therapy Inc.","startDate":"2017-02-20","conditions":["Alzheimer Disease"],"enrollment":100,"completionDate":"2019-10-20"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"CHROMIUM"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"CHROMIUM CHROMIC CHLORIDE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Multitrace-4 Neonatal"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Multitrace-5"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Trace Elements 4"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Multitrace -4 Pediatric"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Multitrace-5"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"29","NDDF":"000862","UNII":"KB1PCR9DMW","CHEBI":"CHEBI:53351","VANDF":"4018528","RXNORM":"21009","UMLSCUI":"C0055617","chemblId":"CHEMBL1200528","ChEMBL_ID":"CHEMBL1200528","KEGG_DRUG":"D03479","DRUGBANK_ID":"DB09129","PUBCHEM_CID":"24808","SECONDARY_CAS_RN":"10060-12-5","MESH_SUPPLEMENTAL_RECORD_UI":"C022990"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","company":"Hospira, Inc.","brandName":"CHROMIUM","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1986-","companyName":"Pfizer","relationship":"Original Developer"}],"publicationCount":137,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Hospira","recentPublications":[{"date":"2024 Jul","pmid":"38885863","title":"Co-production of fermentable sugars and highly active lignin from eucalyptus via a mild preprocessing with diethylene glycol and chromic chloride.","journal":"International journal of biological macromolecules"},{"date":"2023 Mar 9","pmid":"36976162","title":"Ecosystem Protection through Myco-Remediation of Chromium and Arsenic.","journal":"Journal of xenobiotics"},{"date":"2021 Sep 1","pmid":"34470861","title":"Making Weak Antigens Strong: Coupling Antigens to Red Blood Cells.","journal":"Cold Spring Harbor protocols"},{"date":"2018 Mar","pmid":"29207354","title":"Biomonitoring chromium III or VI soluble pollution by moss chlorophyll fluorescence.","journal":"Chemosphere"},{"date":"2017 May","pmid":"27761845","title":"Effects of Excess Cr(3+) on Trace Element Contents in the Brain and Serum in Chicken.","journal":"Biological trace element research"}],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Somerset Theraps Llc"],"status":"approved","companyName":"Hospira","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1986","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1986-06-26T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-08-29T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":"NDA018961"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-11-18T00:00:00.000Z","mah":"SOMERSET THERAPS LLC","brand_name_local":null,"application_number":"ANDA218538"},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T02:03:47.888502+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}